<div class="gmail_quote">2012/2/25 spike <span dir="ltr"><<a href="mailto:spike66@att.net">spike66@att.net</a>></span><br><blockquote class="gmail_quote" style="margin:0 0 0 .8ex;border-left:1px #ccc solid;padding-left:1ex">
<div link="blue" vlink="purple" lang="EN-US"><div><p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1f497d"><u></u> <u></u></span></p><p class="MsoNormal">Finally an article with at least a little technical detail.  The long-prevailing model for age-related brain degradation counter-indicated bexarotene, but the test results were a surprise.  Check out the last two paragraphs below.<u></u><u></u></p>
<p class="MsoNormal"><u></u> <u></u></p><p class="MsoNormal"><u></u> <u></u></p><p class="MsoNormal"><a href="http://www.bioworld.com/content/eisai-lymphoma-drug-reverses-alzheimers-disease-symptoms-0" target="_blank">http://www.bioworld.com/content/eisai-lymphoma-drug-reverses-alzheimers-disease-symptoms-0</a><u></u><u></u></p>
<p class="MsoNormal"><br></p></div></div></blockquote></div><br>So, it would appear that bexarotene is still in play?<br><br>-- <br>Stefano Vaj<br>